


wherein:

V is H or N₃;

W is H or F; or


V and W together are a covalent bond; and

B is a purinyl moiety of Formula VI



optionally substituted at position 2 with OH, SH, NH₂ or halogen, at position 6 with Cl, NH₂, OH, or C₁-C₃ alkyl, and at position 8 with Br or I; or

B is a pyrimidinyl moiety of Formula VII



substituted at position 4 with =O or NH₂ and optionally substituted at position 5 with halogen or C₁-C₃ saturated or unsaturated alkyl optionally substituted 1 to 3 times with halogen CH₃;

or a pharmaceutical salt thereof.

Claims 57-68 (Canceled).


Claim 69 (Original). A method according to Claim 56, wherein said viral infection is caused by HIV-1 virus.

Claim 70 (Original). A method according to Claim 56, wherein said viral infection is caused by hepatitis B.

Claim 71 (Original). A method according to Claim 56, wherein said viral infection is caused by herpes simplex virus.

Claims 72-94 (Canceled).

Claim 95 (Currently Amended). A compound of Formula III




wherein: R_1 is $\text{C}_{11}\text{H}_{23}$ a branched or unbranched, saturated or unsaturated C_6 to C_{18} alkyl group optionally substituted from 1 to 5 times with OH , COOH , oxo, amine, or substituted or unsubstituted aromatic;

X is selected from the group consisting of NHCO , CH_2NCO , CONH , CONCH_3 , S , SO , SO_2 , O , NH , and NCH_3 ;


R_2 is $\text{C}_{10}\text{H}_{21}$ a branched or unbranched, saturated or unsaturated C_6 to C_{14} alkyl group optionally substituted from 1 to 5 times with OH , COOH , oxo, amine, or substituted or unsubstituted aromatic;

Y is selected from the group consisting of NHCO , CH_2NCO , CONH , CONCH_3 , S , SO , SO_2 , O , NH , and NCH_3 ; and


Z is a moiety of the Formula V,



wherein: V is H or N₃;
W is H or F; or
V and W together are a covalent bond; and
B is a purinyl moiety of Formula VI




~~optionally substituted at position 2 with OH, SH, NH₂ or halogen, at position 6 with Cl, NH₂, OH, or C₁-C₃ alkyl, and at position 8 with Br or I; or~~
B is a pyrimidinyl moiety of Formula VII




~~substituted at position 4 with =O or NH₂ and optionally substituted at position 5 with halogen or C₁-C₃ saturated or unsaturated alkyl optionally substituted 1 to 3 times with halogen CH₃.~~

Claims 96-106 (Canceled).


Claim 107 (Currently Amended). ~~The method of claim 56A~~ a method of combating a viral infection in a subject in need of such treatment, wherein the viral infection comprises a virus selected from the group consisting of HIV-1, HBV, herpes virus, influenza, respiratory syncytial virus, mumps, measles, and parainfluenza virus, the method comprising administering to said subject an effective infection-combating amount of a compound of Formula III



wherein: R₁ is C₁₂H₂₅;
X is O;
R₂ is C₁₀H₂₁;
Y is O; and
Z is a moiety of the Formula V,




wherein: V is N₃;
W is H; and
B is a pyrimidinyl moiety of Formula VII



substituted at position 4 with =O and substituted at position 5 with CH₃.

Claim 108 (Canceled).

Claim 109 (Currently Amended). ~~The compound of claim 95A~~ a compound of Formula III




wherein: R₁ is C₁₂H₂₅;

X is O;


R₂ is C₁₀H₂₁;

Y is O; and

Z is a moiety of the Formula V,



wherein: V is N₃;
W is H; and
B is a pyrimidinyl moiety of Formula VII



substituted at position 4 with =O and substituted at position 5 with CH₃.

Sub
HI

Claim 110 (New). A method according to Claim 107, wherein said viral infection is caused by HIV-1 virus.

Claim 111 (New). A method according to Claim 107, wherein said viral infection is caused by hepatitis B.

Claim 112 (New). A method according to Claim 107, wherein said viral infection is caused by herpes simplex virus.